This Small Biotech Is Building on a Surprising Success

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Apr 25, 2018 at 9:52 AM.

  1. #1 cafead, Apr 25, 2018 at 9:52 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,013
    Likes Received:
    3
    via One of the surprises in AbbVie's fourth-quarter results that led to a 14% jump in the stock price the day they were announced was the success of its recently launched drug for treating hepatitis C virus (HCV), Mavyret. CEO Richard Gonzalez said the drug finished 2017 with a 32% market share in the U.S. and was a factor in the decision to increase sales guidance for 2018.

    article source
     
    Quote

Reply to Thread